Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process. Healthcare is on the cusp of a ...
In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is similarly ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
The Carnegie Institution for Science and the University of Massachusetts Medical School (UMMS) have been granted United States Patent 8,283,329, entitled, "Genetic inhibition of double-stranded RNA." ...
Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...
Hosted on MSN
UNC advances RNAi potency platform
Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results